FDA通過史丹佛加速智慧神經調節療法(SAINT)
Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT)
(On September 6, 2022, the U.S. Food and Drug Administration cleared the way for marketing of a rapid-acting brain-stimulation approach for major depressive disorder pioneered by Nolan Williams, M.D., of Stanford University, and colleagues.)
重點:
1. 需使用fMRI定位(Resting-state functional MRI was used to individually target the region of the left dorsolateral prefrontal cortex most functionally anticorrelated with the subgenual anterior cingulate cortex.)
2. 一天10次連續五天(Fifty iTBS sessions (1,800 pulses per session, 50-minute intersession interval) were delivered as 10 daily sessions over 5 consecutive days at 90% resting motor threshold (adjusted for cortical depth).
